Technology and Knowledge Diffusion

Building Greater Resilience in Vaccine Manufacturing – McKinsey & Company

Preparing for the next pandemic is a priority for many national public-health leaders and requires them to lay the groundwork to mount an effective vaccine response.

Decision makers could set the stage for vaccine resilience by defining what their countries and regions need; assessing the local capacity to scale production of vaccine doses; identifying gaps and weaknesses in their national and regional vaccine value chains.

Read the full article here.

View Post

Seminar hosted by the Geneva Network about Availability of COVID Solutions

On 5 October 2022, the Geneva Network organized a panel about the possible future implications of expanding the scope of the TRIPS waiver, in particular in relation to innovation and availability of diagnostics, therapeutics, and vaccines for health crises. Innovation Council’s Executive Director Jennifer Brant took part in this panel to share information about how bio-manufacturing infrastructure can be extended, and what policy actions governments can take to accelerate the process. She expressed the view that the June 2022 TRIPS waiver should be tested, and that evidence should be tabled as to the need to expand the waiver’s scope to cover additional categories of COVID health products, before WTO Members take further action.

Click here to watch the virtual meeting.

View Post

Geneva Network Analysis of the TRIPS Waiver

In the coming months WTO Members will continue to discuss whether to modify the TRIPS waiver that was agreed in June 2022 to include COVID therapeutics and diagnostics. Geneva Network has prepared a policy brief that explains why it could be counterproductive to expand the scope of the waiver in this way. The brief is authored by Philip Stevens of the Geneva Network and Prof. Mark Schultz, Director of the Intellectual Property and Technology Law Program at the University of Akron School of Law.

View Post

Compilation of WIPO Case Studies on IP Management by Small and Medium-Sized Enterprises

The WIPO Secretariat has compiled a selection of case studies and success stories obtained from various areas of WIPO, that showcase the use of IP rights by Small and Medium-sized Enterprises (SMEs). They provide a comprehensive overview on how IP is used by entrepreneurs, inventors and creators, to add value to their products, support business growth, create employment and promote economic development.

These stories will be presented from the 17th to the 22nd of October during the Twenty-Ninth Session of the Committee on Development and Intellectual Property (CDIP).

Read the full story.

View Post

USPTO becomes a partner in international green-technology platform, WIPO GREEN

The United States Patent and Trademark Office (USPTO) became a technology partner to the global green-technology platform of the World Intellectual Property Organization (WIPO). WIPO GREEN is a public-private partnership established by WIPO in 2013. Its 145 international partners include major technology companies, intellectual property (IP) offices, business groups, research institutes, and nongovernmental organizations.

The USPTO’s contributions to WIPO GREEN include its own initiatives that are designed to address the challenge of climate change, including:

Click here to read more.

View Post

Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology

Moderna has sued Pfizer and BioNTech for patent infringement, claiming that its rivals’ Covid-19 shot copied technology that Moderna had developed years before the pandemic.

This sets up what could become a protracted and expensive legal battle between the companies behind coronavirus vaccines that have saved millions of lives worldwide and raised hopes for future medical products using similar messenger RNA, or mRNA, technology.

Read the full story here.

View Post

Making Biologics: Strategies and Policies for Enhancing Capacity

The COVID-19 pandemic has shown that the cost of underinvesting in resilient systems for the development, production, and distribution of health technologies is too high.

This paper introduces biologics, describes opportunities in the sector, and provides insights about the processes for manufacturing them. It also identifies the diverse pathways that countries have used in recent years to develop bio-manufacturing capacity. Finally, it looks to the future to identify the government policies and technology solutions that will enable more countries to join global value chains and to produce these life-saving treatments more safely, quickly, and cost-effectively – to the benefit of patients everywhere.

Click here for the full story.

View Post

IP Protection for Artificial Intelligence

Artificial Intelligence is rapidly evolving to provide accurate information and solutions to problems. AI solutions can be extremely useful in many fields of endeavor.

There are various components and aspects of such systems. Currently, there is some uncertainty – especially with respect to patent protection – as to how intellectual property (IP) rights can be used to protect those components along with the outputs of AI systems.

Click here to read more.

View Post

Slideshow: Innovation and the COVID-19 Response

On 26 November 2021 the new research report about the role that intellectual property played in the development, manufacturing, and global distribution of COVID-19 vaccines and therapeutics was launched in Geneva. The report was co-authored by Innovation Council’s very own Jennifer Brant, and Prof. Mark Schultz.

The report is available here, along with a slideshow of the research project.

View Post